Results of multivariate analysis of minimal residual disease and outcomes in AML
| . | Relapse . | Duration of overall survival . | Duration of relapse-free survival . |
|---|---|---|---|
| MRDCons+ | < .001 | .025 | .007 |
| MDR1 phenotype | .03 | NS | NS |
| Unfavorable or intermediate cytogenetic findings | NS | .036 | .025 |
| . | Relapse . | Duration of overall survival . | Duration of relapse-free survival . |
|---|---|---|---|
| MRDCons+ | < .001 | .025 | .007 |
| MDR1 phenotype | .03 | NS | NS |
| Unfavorable or intermediate cytogenetic findings | NS | .036 | .025 |
All data are P values.
MRDCons+ indicates minimal residual disease (≥ 3.5 × 10−4 residual leukemic cells) after consolidation; MDR1, multidrug resistance 1; and NS, not significant.
The results indicated that MRDCons+ status is independently associated with relapse rate, duration of overall survival, and duration of relapse-free survival.